Gregory T Went Net Worth

The estimated Net Worth of Gregory T Went is at least $2.44 Million dollars as of 20 March 2019. Gregory Went owns over 6,319 units of Adamas Pharmaceuticals Inc stock worth over $1,449,112 and over the last 11 years Gregory sold ADMS stock worth over $991,613.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Gregory Went ADMS stock SEC Form 4 insiders trading

Gregory has made over 11 trades of the Adamas Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Gregory sold 6,319 units of ADMS stock worth $50,489 on 20 March 2019.

The largest trade Gregory's ever made was exercising 204,900 units of Adamas Pharmaceuticals Inc stock on 15 June 2016 worth over $385,212. On average, Gregory trades about 14,254 units every 73 days since 2014. As of 20 March 2019 Gregory still owns at least 176,291 units of Adamas Pharmaceuticals Inc stock.

You can see the complete history of Gregory Went stock trades at the bottom of the page.

What's Gregory Went's mailing address?

Gregory's mailing address filed with the SEC is C/O ADAMAS PHARMACEUTICALS, INC., 2200 POWELL ST, STE 220, EMERYVILLE, CA, 94608.

Insiders trading at Adamas Pharmaceuticals Inc

Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney, and William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.

What does Adamas Pharmaceuticals Inc do?

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Complete history of Gregory Went stock trades at Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals Inc executives and stock owners

Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Neil McFarlane,
  Chief Executive Officer, Director
• Vijay Shreedhar,
  Chief Commercial Officer
• Christopher Prentiss,
  Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
• David Mahoney,
  Lead Independent Chairman of the Board
• Martha Demski,
  Independent Director
• William Ericson,
  Independent Director
• Michael Bigham,
  Independent Director
• Mardi Dier,
  Independent Director
• Ivan Lieberburg,
  Independent Director
• John MacPhee,
  Director
• Anna Richo,
  Director
• Adrian Quartel,
  Chief Medical Officer
• Adrian Quartel M.D.,
  Chief Medical Officer
• Eric C. Schlezinger,
  Head of HR
• Dr. Jill M. Jene,
  Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management
• Sarah Mathieson,
  Head of Corp. Communications, Patient Advocacy & Engagement
• Richard H Booth,
  Director
• Rajiv Patni,
  Chief Medical Officer
• Ix Lp Seventh Mdv Partners,...,
  
• William J Dawson,
  Chief Financial Officer
• Natalie Mc Clure,
  SVP, Product Development
• Point Partners Llcjay Jeffr...,
  
• Richard King,
  Chief Operating Officer
• Gregory T Went,
  Chief Executive Officer
• Alfred G Merriweather,
  Chief Financial Officer
• Jennifer J Rhodes,
  General Counsel
• Capital Equity Investments,...,
  10% owner
• Sara Grootwassink Lewis,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Grace Shin,
  General Counsel
• Vii Lpmdv Ix Lp Seventh Mdv...,
  
• Ventures Management Iii, Ll...,
  
• Spyros Papapetropoulos,
  Director